Cytosorbents (CTSO) Total Current Liabilities (2010 - 2026)

Cytosorbents has reported Total Current Liabilities for 17 years, with the latest figure at $16.3 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 67.45% year-over-year to $16.3 million; the trailing twelve-month figure through Mar 2026 stood at $16.3 million (up 67.45% YoY), and the FY2025 full-year result was $9.7 million, down 1.18% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $16.3 million, up from $9.7 million in the prior quarter.
• The five-year high for Total Current Liabilities was $16.3 million in Q1 2026, with the low at $8.3 million in Q3 2024.
• Historically, Total Current Liabilities has averaged $11.0 million across 5 years, with a median of $10.0 million in 2023.
• Annual changes were most pronounced in 2023 — Total Current Liabilities plunged 35.57% — and 2026, when it soared 67.45%.
• Cytosorbents' Total Current Liabilities stood at $9.7 million in 2022, then jumped by 44.48% to $14.0 million in 2023, then decreased by 30.0% to $9.8 million in 2024, then dropped by 1.18% to $9.7 million in 2025, then soared by 67.92% to $16.3 million in 2026.
• The last three Total Current Liabilities figures came in at $16.3 million (Q1 2026), $9.7 million (Q4 2025), and $10.1 million (Q3 2025), per Business Quant data.